📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2. (2014)

First Author: Opriessnig T

Attributed to: Novel strategies to control virus infection and disease funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.vaccine.2014.06.004

PubMed Identifier: 24929119

Publication URI: http://europepmc.org/abstract/MED/24929119

Type: Journal Article/Review

Volume: 32

Parent Publication: Vaccine

Issue: 34

ISSN: 0264-410X